NCT05540977

Brief Summary

Patients were randomly divided into experimental group and control group. The control group received routine postoperative treatment, while the experimental group took donepezil 5mg orally before going to bed every night from the first day after surgery. The catheter was removed and residual urine was measured in both groups 14 days after surgery, the catheter was successfully removed when the residual urine was less than 100ml. After 14 days, the patient was returned to the hospital for residual urine test, and the residual urine was repeated until the residual urine volume was less than or equal to 100ml. The incidence of postoperative urinary retention and adverse drug reactions were compared between the two groups.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
108

participants targeted

Target at P75+ for early_phase_1

Timeline
Completed

Started Aug 2022

Shorter than P25 for early_phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2022

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 9, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 15, 2022

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2023

Completed
Last Updated

September 15, 2022

Status Verified

July 1, 2022

Enrollment Period

10 months

First QC Date

September 9, 2022

Last Update Submit

September 14, 2022

Conditions

Keywords

DonepezilCervical cancerUrinary Retention

Outcome Measures

Primary Outcomes (1)

  • The incidence of urinary retention (residual urine volume < 100ml)

    Residual urine volume

    No more than 6 weeks

Study Arms (2)

Donepezil

EXPERIMENTAL

Patients were randomly divided into experimental group and control group. The experimental group received routine postoperative treatment and took donepezil 5mg orally before going to bed every night from the first day after surgery.

Drug: Donepezil

Usual care

OTHER

Usual care

Other: Usual care

Interventions

Donepezil 5mg QN

Donepezil

Usual care

Usual care

Eligibility Criteria

Age18 Years - 80 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-80 years
  • Patients who meet the diagnostic criteria of cervical cancer in the Guidelines for the Diagnosis and Treatment of Cervical Cancer (the Fourth Edition) and have been diagnosed by cervical biopsy or colposcopy
  • Patients with surgical indications undergoing extensive abdominal total hysterectomy
  • The person who signed the informed consent.

You may not qualify if:

  • Allergic reaction to donepezil hydrochloride, piperidine derivatives or excipients in preparations
  • Patients with "sick sinus syndrome" or other supraventricular heart conduction diseases
  • Accompanied by serious liver, kidney and other organ dysfunction, serious infectious diseases
  • Patients with a history of mental illness and communication disorders
  • Patients with intraoperative injury of urinary system, or postoperative ureteral fistula and vesicovaginal fistula.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510000, China

RECRUITING

MeSH Terms

Conditions

Uterine Cervical NeoplasmsUrinary Retention

Interventions

Donepezil

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesUrination DisordersUrologic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

IndansIndenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPolycyclic Compounds

Central Study Contacts

Qing Chen, MD

CONTACT

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 9, 2022

First Posted

September 15, 2022

Study Start

August 1, 2022

Primary Completion

May 31, 2023

Study Completion

July 15, 2023

Last Updated

September 15, 2022

Record last verified: 2022-07

Data Sharing

IPD Sharing
Will not share

Locations